Free tool
FAERS Monitor: Retacrit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125545 or its brand name (Retacrit, Epoetin Alfa-Epbx). Reports on generic versions are filed under their own applications.
Reports
2,244
Serious
1,516
68% of reports
Hospitalization
679
Death reported
494
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death416
- off label use329
- haemoglobin decreased167
- anaemia109
- asthenia85
- diarrhoea80
- fatigue78
- hospitalisation73
- product dose omission issue61
- nausea58
- pneumonia58
- malaise54
- drug ineffective52
- dyspnoea48
- acute kidney injury45
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 14 |
| 2014 | 13 |
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 39 |
| 2019 | 151 |
| 2020 | 349 |
| 2021 | 327 |
| 2022 | 381 |
| 2023 | 402 |
| 2024 | 199 |
| 2025 | 166 |
| 2026 | 173 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,915 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemoglobin decreasedSignal | 167 | 15.3 | 13.2 | 2,220 |
| anaemiaSignal | 109 | 5.4 | 4.5 | 385 |
| deathSignal | 416 | 4.5 | 4.2 | 1,188 |
| hospitalisationSignal | 73 | 4.5 | 3.6 | 193 |
| off label useSignal | 329 | 3.5 | 3.2 | 617 |
| acute kidney injurySignal | 45 | 2.8 | 2.1 | 49 |
| astheniaSignal | 85 | 2.1 | 1.7 | 50 |
| product dose omission issue | 61 | 1.9 | 1.5 | 27 |
| pneumonia | 58 | 1.7 | 1.3 | 15 |
| diarrhoea | 80 | 1.2 | 0.9 | 2 |
| malaise | 54 | 1.2 | 0.9 | 1 |
| fatigue | 78 | 0.9 | 0.8 | 0 |
| dyspnoea | 48 | 0.8 | 0.6 | 2 |
| nausea | 58 | 0.7 | 0.5 | 8 |
| drug ineffective | 52 | 0.4 | 0.3 | 59 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.